Cargando…
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retros...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860946/ https://www.ncbi.nlm.nih.gov/pubmed/36680233 http://dx.doi.org/10.3390/v15010193 |
_version_ | 1784874718321442816 |
---|---|
author | Malagnino, Vincenzo Salpini, Romina Teti, Elisabetta Compagno, Mirko Ferrari, Ludovica Mulas, Tiziana Svicher, Valentina Zordan, Marta Basso, Monica Battagin, Giuliana Panese, Sandro Rossi, Maria Cristina Scaggiante, Renzo Zago, Daniela Iannetta, Marco Parisi, Saverio Giuseppe Andreoni, Massimo Sarmati, Loredana |
author_facet | Malagnino, Vincenzo Salpini, Romina Teti, Elisabetta Compagno, Mirko Ferrari, Ludovica Mulas, Tiziana Svicher, Valentina Zordan, Marta Basso, Monica Battagin, Giuliana Panese, Sandro Rossi, Maria Cristina Scaggiante, Renzo Zago, Daniela Iannetta, Marco Parisi, Saverio Giuseppe Andreoni, Massimo Sarmati, Loredana |
author_sort | Malagnino, Vincenzo |
collection | PubMed |
description | The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35–14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC. |
format | Online Article Text |
id | pubmed-9860946 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98609462023-01-22 Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort Malagnino, Vincenzo Salpini, Romina Teti, Elisabetta Compagno, Mirko Ferrari, Ludovica Mulas, Tiziana Svicher, Valentina Zordan, Marta Basso, Monica Battagin, Giuliana Panese, Sandro Rossi, Maria Cristina Scaggiante, Renzo Zago, Daniela Iannetta, Marco Parisi, Saverio Giuseppe Andreoni, Massimo Sarmati, Loredana Viruses Article The aim of this study was to evaluate whether the presence of anti-hepatitis B (HBV) c antibodies (HBcAb positivity) could influence the control of HIV viremia in patients living with HIV (PLWH) who switch to two-drug antiretroviral therapy (2DR) containing lamivudine (3TC) (2DR-3TC-based). A retrospective multicentre observational study was conducted on 160 PLWH switching to the 2DR-3TC-based regimen: 51 HBcAb-positive and 109 HBcAb-negative patients. The HBcAb-positive PLWH group demonstrated a significantly lower percentage of subjects with HIV viral suppression with target not detected (TND) at all time points after switching (24th month: 64.7% vs. 87.8%, p < 0.0001; 36th month 62.7% vs. 86.8%, p = 0.011; 48th month 57.2% vs. 86.1%, p = 0.021 of the HBcAb-positive and HBcAb-negative groups, respectively). Logistic regression analysis showed that the presence of HBcAb positivity (OR 7.46 [95% CI 2.35–14.77], p = 0.004) could favour the emergence of HIV viral rebound by nearly 54% during the entire study follow-up after switching to 2DR-3TC. MDPI 2023-01-10 /pmc/articles/PMC9860946/ /pubmed/36680233 http://dx.doi.org/10.3390/v15010193 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Malagnino, Vincenzo Salpini, Romina Teti, Elisabetta Compagno, Mirko Ferrari, Ludovica Mulas, Tiziana Svicher, Valentina Zordan, Marta Basso, Monica Battagin, Giuliana Panese, Sandro Rossi, Maria Cristina Scaggiante, Renzo Zago, Daniela Iannetta, Marco Parisi, Saverio Giuseppe Andreoni, Massimo Sarmati, Loredana Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title | Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title_full | Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title_fullStr | Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title_full_unstemmed | Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title_short | Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort |
title_sort | role of hbcab positivity in increase of hiv-rna detectability after switching to a two-drug regimen lamivudine-based (2dr-3tc-based) treatment: months 48 results of a multicenter italian cohort |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860946/ https://www.ncbi.nlm.nih.gov/pubmed/36680233 http://dx.doi.org/10.3390/v15010193 |
work_keys_str_mv | AT malagninovincenzo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT salpiniromina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT tetielisabetta roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT compagnomirko roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT ferrariludovica roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT mulastiziana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT svichervalentina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT zordanmarta roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT bassomonica roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT battagingiuliana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT panesesandro roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT rossimariacristina roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT scaggianterenzo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT zagodaniela roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT iannettamarco roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT parisisaveriogiuseppe roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT andreonimassimo roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort AT sarmatiloredana roleofhbcabpositivityinincreaseofhivrnadetectabilityafterswitchingtoatwodrugregimenlamivudinebased2dr3tcbasedtreatmentmonths48resultsofamulticenteritaliancohort |